Document is current
Any future updates will be listed below
-
Authors
Di Staso, Rossana
Casadei, Beatrice
Locke, Frederick L.
Jain, Michael
Voorhees, Timothy J.
Kittai, Adam S. https://orcid.org/0000-0002-4891-6144
Bastos-Oreiro, Mariana
Gutiérrez, Antonio https://orcid.org/0000-0001-9062-077X
Martin Garcia-Sancho, Alejandro https://orcid.org/0000-0001-6330-1028
Terol, Maria Jose
Mead, Monica https://orcid.org/0000-0001-9175-0189
Maranzano, Michael J.
Iacoboni, Gloria
Barba, Pere https://orcid.org/0000-0003-1038-5197
Kwon, Mi
Bailen, Rebeca
Reguera-Ortega, Juan Luis
Mian, Agrima
Hill, Brian
Bachy, Emmanuel
Morschhauser, Franck
Houot, Roch
Thieblemont, Catherine https://orcid.org/0000-0002-9941-2448
Le Gouill, Steven
Masetti, Riccardo
Gori, Davide
Broccoli, Alessandro
Zinzani, Pier Luigi https://orcid.org/0000-0002-2112-2651
Argnani, Lisa https://orcid.org/0000-0003-4225-4626
-
Funding
Funding for this research was provided by:
Università di Bologna (ALMAIDEA2022CUP:J33C22001420001)
- License Information
-
More Information
Article History
Received: 30 July 2024
Revised: 23 October 2024
Accepted: 29 October 2024
First Online: 7 November 2024
Competing interests
: GI served as consultant and received honoraria from Novartis, Roche, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Janssen, Sandoz, Miltenyi, AstraZeneca. PB as consultant and received honoraria from Allogene, Amgen, Autolus, BMS/Celgene, Kite/Gilead, Incyte, Miltenyi Biomedicine, Novartis, Nektar, Pfizer, Pierre Fabre. JLR served as consultant and received honoraria from Johnson&Johnson, Kite/Gilead, Novartis, BMS and Sanofi. RH served as consultant and received honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda, Roche, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte, Miltenyi. AMG served as consultant and received honoraria from Roche, BMS, Takeda, Janssen, Kyowa Kirin, Gilead/Kite, Incyte, Lilly, Miltenyi, Ideogen, Genmab, AbbVie, Sobi, AstraZeneca, GSK. MBO served as consultant and received honoraria from Roche, BMS, Novartis, Janssen, Kyowa Kirin, Gilead/Kite, Incyte, Lilly, Genmab, AbbVie, Sobi, AstraZeneca. The remaining authors declare no competing interests.
: Formal ethical approval was not needed as this is a secondary research and patient have already signed written informed consent for each study analyzed in the present manuscript.
